Lempo Therapeutics

Biotechnology Research • Binyamina - Givat Ada, Haifa District, Israel • 1-10 Employees

Company overview

Headquarters	Binyamina - Givat Ada, Haifa District, Israel
Phone number	+9723050000
Website	lempo-tx.com
Keywords	Stem Cells, MPO, Crispr, PAH, Pulmonary Arterial Hypertension, Gene Editing, Immune, Myeloperoxidase, Netosis
Employees	1-10
Socials

Key Contact at Lempo Therapeutics

Oren Glanz

Co-Founder and CEO

About Lempo Therapeutics

We are a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat severe diseases. Our patented novel treatment uses ex-vivo stem cells gene-editing technique to minimize the collateral damage caused by the immune system as a result of its activity. By doing so, we expect to attenuate the progression of these diseases significantly. We focus first on treating Pulmonary Arterial Hypertension (PAH), a rare, devastating cardiovascular disease which, if left untreated, leads to heart failure and death. There is currently no cure for this disease, and the primary aims of the current treatments are to improve symptoms and increase exercise tolerance. Our concept has already been proven to work in animal models of Alzheimer's Disease, Multiple Sclerosis, cardiovascular diseases, and more.

Lempo Therapeutics revenue & valuation

Annual revenue	$256,665
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$821,328
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

Lempo Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Lempo Therapeutics has never raised funding before.